Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors
ObjectiveEvidence suggests that individuals who had survived to coronavirus disease, 2019 (COVID-19) could develop neuropathic post-COVID pain. This study investigated the association of serological biomarkers and treatments received during hospitalization with development of neuropathic-associated...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1301970/full |
| _version_ | 1827631495406157824 |
|---|---|
| author | César Fernández-de-las-Peñas César Fernández-de-las-Peñas Carlos Guijarro Carlos Guijarro María Velasco-Arribas María Velasco-Arribas Juan Torres-Macho Juan Torres-Macho Ana Franco-Moreno Andrea Truini Oscar Pellicer-Valero Lars Arendt-Nielsen Lars Arendt-Nielsen Lars Arendt-Nielsen |
| author_facet | César Fernández-de-las-Peñas César Fernández-de-las-Peñas Carlos Guijarro Carlos Guijarro María Velasco-Arribas María Velasco-Arribas Juan Torres-Macho Juan Torres-Macho Ana Franco-Moreno Andrea Truini Oscar Pellicer-Valero Lars Arendt-Nielsen Lars Arendt-Nielsen Lars Arendt-Nielsen |
| author_sort | César Fernández-de-las-Peñas |
| collection | DOAJ |
| description | ObjectiveEvidence suggests that individuals who had survived to coronavirus disease, 2019 (COVID-19) could develop neuropathic post-COVID pain. This study investigated the association of serological biomarkers and treatments received during hospitalization with development of neuropathic-associated symptoms.MethodsOne hundred and eighty-three (n = 183) previously hospitalized COVID-19 survivors during the first wave of the pandemic were assessed in a face-to-face interview 9.4 months after hospitalization. Nineteen serological biomarkers, hospitalization data, and treatment during hospitalization were obtained from medical records. Neuropathic pain symptoms (Self-Report Leeds Assessment of Neuropathic Scale), sleep quality (Pittsburgh Sleep Quality Index), pain catastrophizing (Pain Catastrophizing Scale) and anxiety/depressive levels (Hospital Anxiety and Depression Scale) were assessed.ResultsThe prevalence of post-COVID pain was 40.9% (n = 75). Fifteen (20%) patients reported neuropathic symptoms. Overall, no differences in hospitalization data and serological biomarkers were identified according to the presence or not of neuropathic-associated symptoms. Patients with post-COVID pain had the highest neutrophil count, and post hoc analysis revealed that patients with neuropathic post-COVID associated symptoms had lower neutrophil count (p = 0.04) compared with those without neuropathic pain, but differences were small and possible not clinically relevant. No differences in fatigue, dyspnea, brain fog, anxiety or depressive levels, poor sleep, or pain catastrophism between patients with and without neuropathic symptoms were found.ConclusionIt seems that neuropathic-like post-COVID pain symptoms are not associated with neither of assessed serological biomarkers at hospital admission nor hospitalization treatments received in this cohort of hospitalized COVID-19 survivors. |
| first_indexed | 2024-03-09T14:22:50Z |
| format | Article |
| id | doaj.art-868eee104ad9458b8fa2220a70436ff8 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-09T14:22:50Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-868eee104ad9458b8fa2220a70436ff82023-11-28T09:54:58ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-11-011010.3389/fmed.2023.13019701301970Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivorsCésar Fernández-de-las-Peñas0César Fernández-de-las-Peñas1Carlos Guijarro2Carlos Guijarro3María Velasco-Arribas4María Velasco-Arribas5Juan Torres-Macho6Juan Torres-Macho7Ana Franco-Moreno8Andrea Truini9Oscar Pellicer-Valero10Lars Arendt-Nielsen11Lars Arendt-Nielsen12Lars Arendt-Nielsen13Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid, SpainCenter for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, DenmarkDepartment of Internal Medicine-Infectious Department, Research Department, Hospital Universitario Fundación Alcorcón, Madrid, SpainDepartment of Medicine, Universidad Rey Juan Carlos (URJC), Madrid, SpainDepartment of Internal Medicine-Infectious Department, Research Department, Hospital Universitario Fundación Alcorcón, Madrid, SpainDepartment of Medicine, Universidad Rey Juan Carlos (URJC), Madrid, SpainDepartment of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, SpainDepartment of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, SpainDepartment of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, SpainDepartment of Human Neuroscience, Sapienza University, Rome, ItalyImage Processing Laboratory (IPL), Parc Científic de la Universitat de València, Valencia, SpainCenter for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, DenmarkMech-Sense, Department of Gastroenterology and Hepatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark0Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, Aalborg, DenmarkObjectiveEvidence suggests that individuals who had survived to coronavirus disease, 2019 (COVID-19) could develop neuropathic post-COVID pain. This study investigated the association of serological biomarkers and treatments received during hospitalization with development of neuropathic-associated symptoms.MethodsOne hundred and eighty-three (n = 183) previously hospitalized COVID-19 survivors during the first wave of the pandemic were assessed in a face-to-face interview 9.4 months after hospitalization. Nineteen serological biomarkers, hospitalization data, and treatment during hospitalization were obtained from medical records. Neuropathic pain symptoms (Self-Report Leeds Assessment of Neuropathic Scale), sleep quality (Pittsburgh Sleep Quality Index), pain catastrophizing (Pain Catastrophizing Scale) and anxiety/depressive levels (Hospital Anxiety and Depression Scale) were assessed.ResultsThe prevalence of post-COVID pain was 40.9% (n = 75). Fifteen (20%) patients reported neuropathic symptoms. Overall, no differences in hospitalization data and serological biomarkers were identified according to the presence or not of neuropathic-associated symptoms. Patients with post-COVID pain had the highest neutrophil count, and post hoc analysis revealed that patients with neuropathic post-COVID associated symptoms had lower neutrophil count (p = 0.04) compared with those without neuropathic pain, but differences were small and possible not clinically relevant. No differences in fatigue, dyspnea, brain fog, anxiety or depressive levels, poor sleep, or pain catastrophism between patients with and without neuropathic symptoms were found.ConclusionIt seems that neuropathic-like post-COVID pain symptoms are not associated with neither of assessed serological biomarkers at hospital admission nor hospitalization treatments received in this cohort of hospitalized COVID-19 survivors.https://www.frontiersin.org/articles/10.3389/fmed.2023.1301970/fullCOVID-19neuropathic painpost-COVIDbiomarkershospitalization |
| spellingShingle | César Fernández-de-las-Peñas César Fernández-de-las-Peñas Carlos Guijarro Carlos Guijarro María Velasco-Arribas María Velasco-Arribas Juan Torres-Macho Juan Torres-Macho Ana Franco-Moreno Andrea Truini Oscar Pellicer-Valero Lars Arendt-Nielsen Lars Arendt-Nielsen Lars Arendt-Nielsen Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors Frontiers in Medicine COVID-19 neuropathic pain post-COVID biomarkers hospitalization |
| title | Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors |
| title_full | Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors |
| title_fullStr | Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors |
| title_full_unstemmed | Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors |
| title_short | Neuropathic post-COVID pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in COVID-19 survivors |
| title_sort | neuropathic post covid pain symptomatology is not associated with serological biomarkers at hospital admission and hospitalization treatment in covid 19 survivors |
| topic | COVID-19 neuropathic pain post-COVID biomarkers hospitalization |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1301970/full |
| work_keys_str_mv | AT cesarfernandezdelaspenas neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT cesarfernandezdelaspenas neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT carlosguijarro neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT carlosguijarro neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT mariavelascoarribas neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT mariavelascoarribas neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT juantorresmacho neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT juantorresmacho neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT anafrancomoreno neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT andreatruini neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT oscarpellicervalero neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT larsarendtnielsen neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT larsarendtnielsen neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors AT larsarendtnielsen neuropathicpostcovidpainsymptomatologyisnotassociatedwithserologicalbiomarkersathospitaladmissionandhospitalizationtreatmentincovid19survivors |